Market Research Logo

Biopharmaceutical Contract Manufacturing Market, 2017 - 2027

Biopharmaceutical Contract Manufacturing Market, 2017 - 2027

Over the years, the biopharmaceutical market has grown into a prominent and promising segment of the overall pharmaceutical industry. Characterized by a number of blockbuster therapies (HUMIRA®, RITUXAN®, Lantus®, Avastin®, Herceptin® and REMICADE®) and a robust pipeline of product / therapy candidates, the market is poised for significant growth in the coming years. It is worth mentioning that much of the anticipated success of the biopharmaceutical market is dependent on new biologics, which are currently under development, and biosimilars, which are generic versions of these biologics. The field continues to witness significant growth in terms of innovation; this activity is clearly indicative of the growing demand for biologics to cater to existing unmet needs in the industry.

It is necessary to highlight the fact that the development and manufacturing processes for biologics are complex, and usually require advanced capabilities and specialized expertise. In addition, the costs associated with acquiring capabilities in this field are exorbitant and, therefore, it is difficult for companies with limited finances and capacity constraints to succeed by themselves. These complications have led many stakeholders in the biopharmaceutical industry to outsource significant parts of their business operations to contract service providers.

As a result of the above mentioned industry dynamics, the contract manufacturing industry landscape is steadily evolving. CMOs aiming to consolidate their presence in the market are rapidly expanding their service portfolios to provide end-to-end services to their clients and sponsors.

SCOPE OF THE REPORT
The ‘Biopharmaceutical Contract Manufacturing Market (2nd edition), 2017 - 2027’ report provides an extensive study of the contract manufacturing market for biopharmaceuticals. As the biotechnology industry continues to strive to maximize profits, outsourcing has emerged as a promising trend. The study features in-depth analysis, highlighting capabilities of a diverse set of biopharmaceutical CMOs. In addition to other elements, it provides information on the following:
The competitive market landscape and industry analysis based on a number of parameters, such as geographical location, scale of operation, type of biologics manufactured, expression systems used, type of bioreactors used, mode of operation of bioreactors and bioprocessing capacity. 
Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing and packaging of biologics. Each profile provides an overview of the company, its financial performance, information on its manufacturing service and facilities, partnerships and recent developments. 
A detailed discussion on the key enablers, including certain niche sub-segments, such as ADCs, bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market.
A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical contract service providers. 
A detailed capacity analysis, based on global, market wide research on the individual development and manufacturing capacities of various stakeholders in the market. The analysis takes into consideration the average capacities of small, mid-sized, large and very large CMOs, and is based on robust data collection done via both secondary and primary research. 
Information on other aspects of biopharmaceutical outsourcing, which include the growing number of collaborations, partnerships and investments in facility expansions. 
Affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution.

One of the key focus areas of the study was to estimate size of the future opportunity for biopharmaceutical CMOs over the coming decade. In order to provide a detailed future outlook, our projections have been segmented on the basis of commonly outsourced business operations (Active Pharmaceutical Ingredients (APIs) and Finished Dosage Formulations (FDFs)), types of expression systems and key geographical regions. The base year for the report is 2017, and it provides a detailed market forecast for the period between 2017 and 2027.

The research, analysis and insights presented in this report is backed by a deep understanding of insights gathered both from secondary and primary sources. For the purpose of the study, we invited more than 200 senior stakeholders in the industry to participate in a survey. This enabled us to solicit their opinions on upcoming opportunities and challenges that must be considered for a more inclusive growth. In addition, the opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with Birgit Schwab (Senior Manager Strategic Marketing, Rentschler Biotechnologie), Claire Otjes (Assistant Marketing Manager, Batavia Biosciences), David C Cunningham (Director Corporate Development, Goodwin Biotechnology), Dietmar Katinger (CEO, Polymun Scientific), Kevin Daley (Director Pharmaceuticals, Novasep Synthesis), Mark Wright (Site Head, Grangemouth, Piramal Healthcare), Raquel Fortunato (CEO, GenIbet Biopharmaceuticals), Sebastian Schuck (Head of Business Development, Wacker Biotech), Stephen Taylor (Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies) and Tim Oldham (CEO, Cell Therapies).

It is worth highlighting that the biopharmaceutical market is characterized by a huge unmet need for adequate manufacturing facilities and expertise. Given the inherent complexities associated with the development of biologics, the aforementioned need is likely to translate into promising business opportunities for CMOs.

EXAMPLE HIGHLIGHTS
1. During our research, we came across more than 200 companies offering contract manufacturing services for biopharmaceuticals. These companies possess the capabilities to handle multiple types of biologics; majority of firms offer services related to proteins and peptides (138), antibodies (116), and vaccines (79). Mammalian based manufacturing, the predominant approach, is expected to continue to achieve a relatively higher growth rate in the near future.
2. Developed regions, such as Europe and North America, currently dominate the biopharmaceutical contract manufacturing landscape. In fact, we identified close to 100 biopharmaceutical manufacturing facilities each, belonging to various players, in both Europe and North America. In addition to the developed regions, we observed that a number of prominent global and indigenous players have facilities (60) based in emerging regions of Asia and rest of the world; examples include (in alphabetical order) BioCell, CinnaGen, Cell Therapies, Concord Biotech, EirGenix, GE Healthcare, Kemwell Biopharma, LuinaBio, Meridian Life Science, Piramal Pharma Solutions, and WuXi AppTec (WuXi Biologics).
3. During our research, we identified that 69% of all CMOs offer commercial scale manufacturing services; it is also worth highlighting that 27% of all CMOs offer end-to-end services across all scales of operation; examples of such players include 3P Biopharmaceuticals, Batavia Biosciences, CARBOGEN AMCIS, Cobra Biologics and IDT Biologika.
4. The current global contract biopharmaceutical manufacturing capacity is estimated to be over 3.4 million liters. Established players, such as AbbVie Contract Manufacturing, Celltrion, FUJIFILM Diosynth Biotechnologies, Lonza, Samsung BioLogics and ST Pharm contribute a significant proportion to the overall supply. Having said that, of the over 200 CMOs we evaluated, more than 150 are relatively small or mid-sized companies; such companies are one of the key driving forces behind the heightened pace of biopharmaceutical research and development.
5. Niche and emerging therapeutic classes hold significant promise for biopharmaceutical CMOs. The rapidly growing development pipeline of antibody drug conjugates and bispecific antibodies (100+ molecules each) are likely to translate into tangible growth opportunities. In addition to antibody based therapeutics, cell and gene therapy manufacturing are other opportunities that are likely to unfold in the near future. CMOs such as 3P Biopharmaceuticals, apceth Biopharma, Batavia Biosciences, Brammer Bio, Cell and Gene Therapy Catapult, Cobra Biologics, KBI Biopharma, Meridian Life Science, Waisman Biomanufacturing and WuXi AppTec are actively offering services related to these complex biologics.
6. As numerous biopharmaceuticals near patent expiry, a wave of follow-on biologics and biosimilars are anticipated to soon enter the market. As of January 2017, there were over 800 biosimilars under development. Upcoming patent expiries of blockbuster therapies, such as infliximab, trastuzumab and adalimumab, are likely to translate into huge growth opportunities for the biosimilars market, which is likely to result in a surge in the demand for contract services providers.
7. Over 450 deals have been inked in the biopharmaceutical contract manufacturing market in the past decade. Although a significant proportion of these agreements focus on manufacturing (37%), we came across a number of acquisitions / mergers (13%) and specific collaborations (8%) where partner companies have opted to work together in order to significantly expand their respective service portfolios. Several companies have entered into multiple collaborations; these include Lonza (34), CMC Biologics (21), Emergent BioSolutions (20), Charles River Laboratories (19) and Goodwin Biotechnology (18). In addition, multiple players have made significant investments in expanding their existing operations, acquiring new facilities and / or capabilities. We came across more than 150 such instances over the past decade.
8. Driven by increasing global demand and the rapidly expanding biopharmaceutical market, we expect the overall contract manufacturing market in the biopharmaceuticals domain to grow at an annualized rate of 8.7% between 2017 and 2027. The growth is likely to be higher in emerging markets of Asia and rest of the world.

RESEARCH METHODOLOGY
Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 provides an executive summary of the key insights captured in our research. The summary offers a high level view on the current status of the biopharmaceutical contract manufacturing market and where it is headed in the mid-long term.

Chapter 3 is a general introduction to biopharmaceuticals and biopharmaceutical manufacturing processes. The chapter also includes an overview of the various expression systems used for the development of different biologics and biotherapeutic products. It features a brief overview of contract manufacturing and also includes detailed discussion on the need for outsourcing in this field. We have also presented a list of commonly outsourced biomanufacturing activities; the chapter concludes with a discussion on the challenges that are currently associated with the market.

Chapter 4 provides a comprehensive view on the global landscape of biopharmaceutical CMOs. It features an in-depth market review, including regional distribution, analysis by scale of operation, type of biologics manufactured and expression systems. Moreover, the chapter provides information on the production capabilities of CMOs, based on type of bioreactor, mode of operation of bioreactors and fermentation capacity.

Chapter 5 features detailed profiles of some of the key players that are active in the biopharmaceutical contract manufacturing market in the US. Each profile presents a brief overview of the company, its contract service offerings, financial information, manufacturing capabilities and facilities, partnerships, recent developments, and awards and accolades received. The chapter also provides insights on the overall evolution of the biopharmaceutical contract manufacturing market in the US, specifically distributed on the basis of type of service and expression system used, for the period between 2017 and 2027.

Chapter 6 features detailed profiles of some of the key players that are active in the biopharmaceutical contract manufacturing market in the Europe. Each profile presents a brief overview of the company, its contract service offerings, financial information, manufacturing capabilities and facilities, partnerships, recent developments, and awards and accolades received. The chapter also provides insights on the overall evolution of the biopharmaceutical contract manufacturing market in Europe, specifically distributed on the basis of type of service and expression system used, for the period between 2017 and 2027.

Chapter 7 features detailed profiles of some of the key players that are active in the biopharmaceutical contract manufacturing market in Asia and other regions of the world. Each profile presents a brief overview of the company, its contract service offerings, financial information, manufacturing capabilities and facilities, partnerships, recent developments, and awards and accolades received. The chapter also provides insights on the overall evolution of the biopharmaceutical contract manufacturing market in the aforementioned regions, specifically distributed on the basis of type of service and expression system used, for the period between 2017 and 2027.

Chapter 8 focuses on some of the niche segments within the biopharmaceutical industry that are expected to drive the demand for outsourcing in this field. These include ADCs, bispecific antibodies, cell therapies and gene therapies. The chapter provides detailed market overviews, including information on the pipeline, partnerships, investments and the presence of CMOs in each of the aforementioned segments.

Chapter 9 is a case study focused on outsourcing of operations related to biosimilars, which represents a major growth opportunity for biopharmaceutical CMOs. It provides an overview of biosimilars and captures information on the various CMOs that are actively involved in this niche market.

Chapter 10 presents an analysis of the recent developments in the biopharmaceutical contract manufacturing market. It provides a detailed list of the various partnerships that have been established in the recent past, along with an overview of other market trends, such as investments and facility expansions.

Chapter 11 features a comprehensive analysis of the global / regional capacity of contract manufacturers that are engaged in the manufacturing of biopharmaceutical products. The results of this analysis were used to gain a more accurate understanding of outsourcing capabilities across different geographies. The analysis represents a holistic view on the supply-side of the market, allowing us to present a highly informed opinion on whether the present capacity will be able to meet the likely future demand.

Chapter 12 presents insights from the survey conducted for this study. We invited over 200 stakeholders involved in the development of different types of gene therapy vectors. The participants, who were primarily Director / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

Chapter 13 presents a detailed market forecast for the biopharmaceutical contract manufacturing market segmented by type of business (APIs and FDFs). It features an analysis of the future of biopharmaceutical related outsourcing activities for certain specific geographies across the globe, and in terms of the type of expression systems used. To account for the uncertain nature of the market, we have presented three different tracks of the market’s evolution, namely the conservative, base and optimistic scenarios.

Chapter 14 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of the contract manufacturing market within the biopharmaceutical industry, under a comprehensive SWOT framework.

Chapter 15 is a summary of the entire report. It provides the key takeaways and presents our independent opinion of the biopharmaceutical CMOs market, based on the research and analysis described in the previous chapters. It also provides a recap of some of the upcoming future trends, which, we believe, are likely to influence the growth of biopharmaceutical CMOs.

Chapter 16 contains the transcripts of interviews conducted with representatives from renowned organizations that are engaged in the biopharmaceutical contract manufacturing domain. In this study, we spoke to Birgit Schwab (Senior Manager Strategic Marketing, Rentschler Biotechnologie), Claire Otjes (Assistant Marketing Manager, Batavia Biosciences), David C Cunningham (Director Corporate Development, Goodwin Biotechnology), Dietmar Katinger (CEO, Polymun Scientific), Kevin Daley (Director Pharmaceuticals, Novasep Synthesis), Mark Wright (Site Head, Grangemouth, Piramal Healthcare), Raquel Fortunato (CEO, GenIbet Biopharmaceuticals), Sebastian Schuck (Head of Business Development, Wacker Biotech), Stephen Taylor (Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies) and Tim Oldham (CEO, Cell Therapies).

Chapter 17 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 18 is an appendix that provides the list of companies and organizations mentioned in the report.

LIST OF COMPANIES AND ORGANIZATIONS
The following companies and organizations have been mentioned in the report:
1. 3P Biopharmaceuticals
2. Aalto Scientific
3. AbbVie Contract Manufacturing
4. AbGenomics
5. Ablynx
6. Abzena
7. ACES Pharma
8. Acticor Biotech
9. Active Biotech
10. Adar Biotech
11. ADC Therapeutics
12. Adimab
13. Advanced BioScience Laboratories (ABL)
14. Advanced Biotherapeutics Consulting (ABC)
15. Affimed
16. Affinity Life Sciences
17. Agensys
18. Ajinomoto Althea
19. Albany Molecular Research (AMRI)
20. Alberta Cell Therapy Manufacturing
21. Alcami
22. Aldevron
23. Allele Biotechnology
24. Alliance Medical Products
25. Alligator Bioscience
26. Allozyne
27. ALMAC Group
28. Altaris Capital Partners
29. AmatsiQBiologicals
30. AmbioPharm
31. Ambrx
32. AmBTU
33. AMEGA Biotech
34. Amgen
35. Amneal Life Sciences
36. AMSBIO
37. Anogen
38. apceth Biopharma
39. Applied Biological Materials
40. Applied Viromics
41. Aptuit
42. Arabio
43. Asahi Glass
44. Aspyrian Therapeutics
45. Astellas Pharma
46. AstraZeneca
47. Asymchem
48. Athenex Pharma Solutions
49. Atlantic Bio GMP
50. AURA Biotechnologies
51. AUSTRIANOVA
52. AutekBio
53. Avecia
54. Avid Biologics
55. Avid Bioservices
56. Bachem
57. Baliopharm
58. Batavia Biosciences
59. Baxter BioPharma Solutions
60. Bayer
61. BCN Peptides
62. Beckman Research Institute
63. Beijing ABT Genetic Engineering Technology
64. Bharat Serums And Vaccines
65. BIBITEC
66. Bicycle Therapeutics
67. BINEX
68. Bio Elpida
69. Bioanalytical Sciences Department, Southern Research
70. BioCell
71. Biocon
72. BioConnection
73. Biofabri
74. Biogen-Idec
75. BioLineRx
76. Biological and Cellular GMP Manufacturing Facility, City of Hope
77. Biological E
78. Biological Process Development Facility, University of Nebraska
79. BioMARC
80. Biomatik
81. Biomay
82. BIOMEVA
83. BiondVax Pharmaceuticals
84. BioPharmaceuticals Australia
85. Biosynergy
86. Bio-Synthesis
87. BioTechLogic
88. BioTechnique
89. Biotechpharma
90. Biotecnol
91. Biotest
92. BioVectra
93. Biovian
94. Blue Stream Laboratories
95. Boehringer Ingelheim
96. Boehringer Ingelheim BioXcellence
97. Brammer Bio
98. Bristol-Myers Squibb
99. Bryllan
100. BSP Pharmaceuticals
101. Cambrex
102. CARBOGEN AMCIS
103. Catalent
104. Catalent Biologics
105. Catalent Pharma Solutions
106. Cedarburg Pharmaceuticals
107. Celgene
108. Cell and Gene Therapy Catapult
109. Cell Culture Company
110. Cell Essentials
111. Cell Therapies
112. Cell Therapy and Regenerative Medicine, University of Utah
113. Celldex Therapeutics
114. CELLforCURE
115. Cellin Technologies
116. Cells for Sight, Stem Cell Therapy Research Unit, University College London
117. Celltrion
118. Cellular Dynamics International (a FUJIFILM company)
119. Cellular Therapeutics
120. Cellular Therapy Integrated Service, Case Western Reserve University
121. Celonic
122. Center for Biocatalysis and Bioprocessing, University of Iowa
123. Center for Biomedical Engineering and Advanced Manufacturing, McMaster University
124. Center for Cell and Gene Processing, Takara Bio
125. Center for Cell and Gene Therapy, Baylor College of Medicine
126. Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia (CHOP)
127. Center of iPS Cell Research and Application, Kyoto University (CiRA)
128. Centre for Commercialization of Regenerative Medicine
129. Centrose
130. Century Pharmaceuticals
131. Cerbios-Pharma
132. CEVEC Pharmaceuticals
133. Charles River Laboratories
134. ChemCon
135. Chemi Peptides
136. ChemPartner
137. Children's GMP / GMP facility St. Jude Children's Research Hospital
138. ChromaCon
139. Cincinnati Children's Hospital Medical Center
140. CinnaGen
141. Clinical Biomanufacturing Facility, University of Oxford
142. Clinical Research Facility, South London and Maudsley
143. CMC Biologics
144. Cobra Biologics
145. Cognate BioServices
146. Coldstream Laboratories
147. Concord Biotech
148. Concortis
149. Cook Pharmica
150. Corden Pharma
151. Covance
152. Creative Biogene
153. Creative Biolabs
154. Cryosite
155. CytomX Therapeutics
156. Cytovance Biologics
157. Daiichi Sankyo
158. Dalton Pharma Services
159. Dishman Group
160. DMBio
161. Dow Pharmaceutical Solutions
162. Dutalys
163. EirGenix
164. Eli Lilly
165. Embio
166. EMD Serono
167. Emergent BioSolutions
168. Emerson
169. Encap Drug Delivery
170. Endo Pharmaceuticals
171. Epigen Biotech
172. Esperance Pharmaceuticals
173. EuBiologics
174. EUCODIS Bioscience
175. EUFETS
176. Eurofins Central Global Laboratory
177. Eurogentec
178. Euticals
179. Evonik
180. Fabion Pharmaceuticals
181. Ferro Pfanstiehl
182. FinVector
183. Formation Biologics
184. Formosa Laboratories
185. Foundation BioPharma
186. Fraunhofer Institute for Cell Therapy and Immunology IZI
187. French National Centre for Scientific Research, Université de Toulouse
188. Frontage Laboratories
189. F-star
190. FUJIFILM Diosynth Biotechnologies
191. Fusimab
192. Fusion Antibodies
193. Gadea Pharmaceutical Group
194. Gala Biotech
195. Gallus BioPharmaceuticals
196. Ganymed Pharmaceuticals
197. Gates Biomanufactuirng Facility
198. GE Healthcare
199. GEG Tech
200. Gene and Cell Therapy Lab, Institute of Translational Health Sciences
201. Gene Medicine Japan / Kobe Biomedical Accelerator
202. Gene Transfer Vector Core (GTVC)
203. Gene Transfer Vector Core, Schepens Eye Research Institute and Massachusetts Eye and Ear Infirmary
204. Gene Transfer, Targeting and Therapeutics Core, Salk Institute for Biological Studies
205. Gene Vector and Virus Core, Stanford Medicine
206. GeneCure Biotechnologies
207. GeneDetect
208. Genentech
209. Genethon
210. GenIbet Biopharmaceuticals
211. Genmab
212. Génopoïétic
213. GenVec
214. Gilead Sciences
215. GIPharma
216. Glenmark Pharmaceuticals
217. Glycotope Biotechnology
218. GNH India
219. Goodwin Biotechnology
220. GOSH Cellular Therapy Laboratories, University College of London
221. GP Pharm
222. Grand River Aseptic Manufacturing
223. Great Point Partners
224. GreenPak Biotech
225. Grünenthal
226. GSEx, The Robinson Research Institute, University of Adelaide
227. GSK
228. GSK-Domantis
229. GTP Technology
230. Guy's and St Thomas' Facility
231. HALIX
232. Harvest Moon Pharmaceuticals
233. Health Biotech
234. Health Sciences Authority
235. Heidelberg Pharma
236. Hepalink
237. Hetero Drugs
238. Histocell
239. Hisun Pharmaceuticals USA
240. Ho Research Consortium
241. Hong Kong Institute of Biotechnology
242. Hope Center Viral Vectors Core, Washington University School of Medicine
243. iBIOSOURCE
244. Icagen
245. IDDI
246. IDT Biologika
247. Igenica Biotherapeutics
248. ImClone Systems
249. ImmunoGen
250. Immunomedics
251. INC Research
252. Indian Immunologicals
253. Inhibrx
254. Inno Biologics
255. Innovent Biologics
256. Intas Pharmaceuticals
257. Integrity Bio
258. International Joint Cancer Institute, Military Medical University
259. Intertek
260. Istituto Biochimico Italiano Giovanni Lorenzini
261. JHL Biotech
262. John Goldmann Centre for Cellular Therapy, Imperial College London
263. Julphar Gulf Pharmaceutical Industries
264. KABS Pharmaceutical Services
265. Kairos Therapeutics
266. Kamat Pharmatech
267. KBI Biopharma
268. Kemwell Biopharma
269. Laboratory for Cell and Gene Medicine, Stanford University
270. LAMPIRE Biological Laboratories
271. Lentigen Technology (wholly owned subsidiary of Miltenyi Biotec)
272. LFB BIOMANUFACTURING
273. Lindis Biotech
274. Lonza
275. LuinaBio
276. MabPlex
277. MacroGenics
278. Maine Biotechnology Services
279. MassBiologics
280. MaSTherCell
281. MBI International
282. MediaPharma
283. MedImmune
284. Medix Biochemica
285. Menarini Biotech
286. Merck
287. Meridian Life Science
288. Merrimack
289. Merro Pharmaceutical
290. Mersana Therapeutics
291. Merus
292. MGH Vector Core (Massachusetts General Hosp


1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Context and Background
3.2. Biopharmaceuticals: An Overview
3.3. Biopharmaceuticals: Manufacturing Process
3.3.1. Types of Expression Systems
3.3.1.1. Bacterial Expression Systems
3.3.1.2. Yeast Expression Systems
3.3.1.3. Insect Expression Systems
3.3.1.4. Plant Expression Systems
3.3.1.5. Mammalian Expression Systems
3.3.2. Processing Steps
3.3.2.1. Upstream Processing
3.3.3.2. Downstream Processing
3.4. Contract Manufacturing: An Overview
3.5. The Need for Outsourcing in the Biopharmaceutical Industry
3.6. Biopharmaceutical Contract Manufacturing: Commonly Outsourced Operations
3.7. Biopharmaceutical Contract Manufacturing: Selecting a CMO Partner
3.8. Biopharmaceutical Contract Manufacturing: Associated Risks and Challenges
4. COMPETITIVE LANDSCAPE
4.1. Chapter Overview
4.1.1. Geographical Presence of Biopharmaceutical CMOs
4.1.2. Analysis by Types of Biologics
4.1.3. Analysis by Scale of Operation
4.1.4. Analysis by Expression Systems
4.1.5. Analysis by Types of Bioreactors and Modes of Operation
4.1.6. Analysis by Manufacturing Capacity
4.1.7. Analysis by Packaging Form
5. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN NORTH AMERICA
5.1. Chapter Overview
5.2. Biopharmaceutical Outsourcing in North America: Regulatory Scenario
5.2.1. Impact of Current Political Situation
5.3. Leading Biopharmaceutical CMOs in North America
5.3.1. AMRI
5.3.1.1. Company Overview
5.3.1.2. Services Portfolio
5.3.1.2.1. Regulatory Support and Quality Assurance
5.3.1.2.2. Biomanufacturing Services
5.3.1.3. Financial Information
5.3.1.4. Manufacturing Facilities
5.3.1.5. Partnerships
5.3.1.6. Recent Developments
5.3.1.7. Awards and Accolades
5.3.1.8. Future Outlook
5.3.2. Baxter BioPharma Solutions
5.3.2.1. Company Overview
5.3.2.2. Services Portfolio
5.3.2.2.1. Biologics Related Services
5.3.2.2.2. Vaccine Related Services
5.3.2.2.3. Regulatory Support
5.3.2.3. Financial Information
5.3.2.4. Manufacturing Facilities
5.3.2.5. Partnerships
5.3.2.6. Recent Developments
5.3.2.7. Awards and Accolades
5.3.3. Catalent
5.3.3.1. Company Overview
5.3.3.2. Services Portfolio
5.3.3.2.1. Cell Line Development
5.3.3.2.2. Manufacturing (Biomanufacturing)
5.3.3.2.3. ADCs and Bioconjugates
5.3.3.2.4. Biosimilars
5.3.3.2.5. Analytical Services
5.3.3.2.6. Clinical Supply Services
5.3.3.2.7. Regulatory Support
5.3.3.3. Financial Information
5.3.3.4. Manufacturing Facilities
5.3.3.5. Partnerships
5.3.3.6. Recent Developments
5.3.3.7. Awards and Accolades
5.3.3.8. Future Outlook
5.3.4. Cytovance Biologics
5.3.4.1. Company Overview
5.3.4.2. Services Portfolio
5.3.4.2.1. R&D Services
5.3.4.2.2. Manufacturing Services
5.3.4.2.3. Purification and Fill/Finish
5.3.4.3. Manufacturing Facilities
5.3.4.4. Partnerships
5.3.4.5. Recent Developments
5.3.4.6. Awards and Accolades
5.3.5. Patheon
5.3.5.1. Company Overview
5.3.5.2. Services Portfolio
5.3.5.2.1. Biologics
5.3.5.2.2. Small Molecules
5.3.5.2.3. Supply Chain Management
5.3.5.3. Financial Information
5.3.5.4. Manufacturing Facilities
5.3.5.5. Partnerships and Acquisitions
5.3.5.6. Recent Developments
5.3.5.7. Awards and Accolades
5.4. Biopharmaceutical Contract Manufacturing in North America: Sub-Market Forecast, 2017-2027
5.4.1. Biopharmaceutical Contract Manufacturing in North America: Distribution by Type of Business Operation, 2017-2027
5.4.2. Biopharmaceutical Contract Manufacturing in North America: Distribution by Expression Systems, 2017-2027
6. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN EUROPE
6.1. Chapter Overview
6.2. Biopharmaceutical Outsourcing in Europe: Regulatory Scenario
6.3. Leading Biopharmaceutical CMOs in Europe
6.3.1. 3P Biopharmaceuticals
6.3.1.1. Company Overview
6.3.1.2. Services Portfolio
6.3.1.3. Manufacturing Facilities
6.3.1.4. Partnerships
6.3.1.5. Recent Developments
6.3.1.6. Awards and Accolades
6.3.2. Boehringer Ingelheim BioXcellence
6.3.2.1. Company Overview
6.3.2.2. Services Portfolio
6.3.2.3. Financial Information
6.3.2.4. Manufacturing Facilities
6.3.2.5. Partnerships
6.3.2.6. Recent Developments
6.3.2.7. Awards and Accolades
6.3.3. Celonic
6.3.3.1. Company Overview
6.3.3.2. Services Portfolio
6.3.3.3. Manufacturing Facilities
6.3.3.4. Partnerships
6.3.3.5. Recent Developments
6.3.4. FUJIFILM Diosynth Biotechnologies
6.3.4.1. Company Overview
6.3.4.2. Services Portfolio
6.3.4.3. Financial Information
6.3.4.4. Manufacturing Facilities
6.3.4.5. Partnerships
6.3.4.6. Recent Developments
6.3.5. LFB Biopharma
6.3.5.1. Company Overview
6.3.5.2. Services Portfolio
6.3.5.3. Financial Information
6.3.5.4. Manufacturing Facilities
6.3.5.5. Partnerships
6.3.5.6. Recent Developments
6.3.6. Lonza
6.3.6.1. Company Overview
6.3.6.2. Services Portfolio
6.3.6.3. Financial Information
6.3.6.4. Manufacturing Facilities
6.3.6.5. Partnerships
6.3.6.6. Recent Developments
6.3.7. Menarini Biotech
6.3.7.1. Company Overview
6.3.7.2. Services Portfolio
6.3.7.3. Partnerships
6.3.8. Novasep
6.3.8.1. Company Overview
6.3.8.2. Services Portfolio
6.3.8.3. Financial Information
6.3.8.4. Manufacturing Facilities
6.3.8.5. Partnerships
6.3.8.6. Recent Developments
6.3.9. Rentschler Biotechnologie
6.3.9.1. Company Overview
6.3.9.2. Services Portfolio
6.3.9.3. Manufacturing Facilities
6.3.9.4. Partnerships
6.3.9.5. Recent Developments
6.4. Biopharmaceutical Contract Manufacturing in Europe: Sub-Market Forecast, 2017-2027
6.4.1. Biopharmaceutical Contract Manufacturing in Europe: Distribution by Type of Business Operation, 2017-2027
6.4.2. Biopharmaceutical Contract Manufacturing in Europe: Distribution by Expression Systems, 2017-2027
7. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN ASIA AND THE REST OF THE WORLD
7.1. Chapter Overview
7.2. Biopharmaceutical Contract Manufacturing in China
7.2.1. Biopharmaceutical Outsourcing in China: Regulatory Scenario
7.2.2. Challenges Faced by CMOs in China
7.3. Leading Biopharmaceutical CMOs in China
7.3.1. Autotek Bio
7.3.1.1. Company Overview
7.3.1.2. Services Portfolio
7.3.1.3. Manufacturing Facilities
7.3.2. WuXi AppTec
7.3.2.1. Company Overview
7.3.2.2. Services Portfolio
7.3.2.3. Financial Information
7.3.2.4. Manufacturing Facilities
7.3.2.5. Partnerships
7.3.2.6. Recent Developments
7.4. Biopharmaceutical Contract Manufacturing in China: Sub-Market Forecast, 2017-2027
7.4.1. Biopharmaceutical Contract Manufacturing in China: Distribution by Type of Business Operation, 2017-2027
7.4.2. Biopharmaceutical Contract Manufacturing in China: Distribution by Expression Systems, 2017-2027
7.5. Biopharmaceutical Contract Manufacturing in India
7.5.1. Biopharmaceutical Outsourcing in India: Regulatory Scenario
7.5.2. Challenges Faced by CMOs in India
7.6. Leading Biopharmaceutical CMOs in India
7.6.1. Intas Pharmaceuticals
7.6.1.1. Company Overview
7.6.1.2. Services Portfolio
7.6.1.3. Financial Information
7.6.1.4. Manufacturing Facilities
7.6.1.5. Partnerships
7.6.2. Kemwell Biopharma
7.6.2.1. Company Overview
7.6.2.2. Services Portfolio
7.6.2.3. Manufacturing Facilities
7.6.2.4. Partnerships
7.6.2.5. Recent Developments
7.6.3. Piramal Pharma Solutions
7.6.3.1. Company Overview
7.6.3.2. Services Portfolio
7.6.3.3. Financial Information
7.6.3.4. Manufacturing Facilities
7.6.3.5. Partnerships
7.6.3.6. Recent Developments
7.6.4. Shashun Pharma
7.6.4.1. Company Overview
7.6.4.2. Services Portfolio
7.6.4.3. Financial Information
7.6.4.4. Manufacturing Facilities
7.6.4.5. Partnerships
7.6.5. Syngene
7.6.5.1. Company Overview
7.6.5.2. Services Portfolio
7.6.5.3. Financial Information
7.6.5.4. Manufacturing Facilities
7.6.5.5. Partnerships
7.7. Biopharmaceutical Contract Manufacturing in India: Sub-Market Forecast, 2017-2027
7.7.1. Biopharmaceutical Contract Manufacturing in India: Distribution by Type of Business Operation, 2017-2027
7.7.2. Biopharmaceutical Contract Manufacturing in India: Distribution by Expression Systems, 2017-2027
7.8. Biopharmaceutical Contract Manufacturing in Japan
7.8.1. Biopharmaceutical Outsourcing in Japan: Regulatory Scenario
7.8.2. Challenges Faced by CMOs in Japan
7.9. Leading Biopharmaceutical CMOs in Japan
7.9.1. Asahi Glass
7.9.1.1. Company Overview
7.9.1.2. Services Portfolio
7.9.1.3. Financial Information
7.9.1.4. Manufacturing Facilities
7.9.1.5. Partnerships
7.10. Biopharmaceutical Contract Manufacturing in Japan: Sub-Market Forecast, 2017-2027
7.10.1. Biopharmaceutical Contract Manufacturing in Japan: Distribution by Type of Business Operation, 2017-2027
7.10.2. Biopharmaceutical Contract Manufacturing in Japan: Distribution by Expression Systems, 2017-2027
7.11. Biopharmaceutical Contract Manufacturing in South Korea
7.11.1. Biopharmaceutical Outsourcing in South Korea: Regulatory Scenario
7.11.2. Challenges Faced by CMOs in South Korea
7.12. Leading Biopharmaceutical CMOs in South Korea
7.12.1. DMBio
7.12.1.1. Company Overview
7.12.1.2. Services Portfolio
7.12.1.3. Manufacturing Facilities
7.12.1.4. Recent Developments
7.12.2. Samsung BioLogics
7.12.2.1. Company Overview
7.12.2.2. Services Portfolio
7.12.2.3. Financial Information
7.12.2.4. Manufacturing Facilities
7.12.2.5. Partnerships
7.12.2.6. Recent Developments
7.13. Biopharmaceutical Contract Manufacturing in South Korea: Sub-Market Forecast, 2017-2027
7.13.1. Biopharmaceutical Contract Manufacturing in South Korea: Distribution by Type of Business Operation, 2017-2027
7.13.2. Biopharmaceutical Contract Manufacturing in South Korea: Distribution by Expression Systems, 2017-2027
7.14. Biopharmaceutical Contract Manufacturing in Australia
7.14.1. Biopharmaceutical Outsourcing in Australia: Regulatory Scenario
7.14.2. Challenges Faced by CMOs in Australia
7.15. Leading Biopharmaceutical CMOs in Australia
7.15.1. Cell Therapies
7.15.1.1. Company Overview
7.15.1.2. Services Portfolio
7.15.1.3. Manufacturing Facilities
7.15.1.4. Partnerships
7.15.1.5. Recent Developments
7.15.2. LuinaBio
7.15.2.1. Company Overview
7.15.2.2. Services Portfolio
7.15.2.3. Manufacturing Facilities
7.15.2.4. Partnerships
8. NICHE SECTORS IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING
8.1. Chapter Overview
8.2. Antibody Drug Conjugates
8.2.1. Introduction
8.2.1.1. Manufacturing Process
8.2.1.2. Key Technologies and Technology Providers
8.2.2. Pipeline Analysis
8.2.2.1. ADC Pipeline: Marketed and Clinical Molecules
8.2.2.2. ADC Pipeline: Preclinical and Discovery Stage Molecules
8.2.3. In-house Manufacturing Scenario
8.2.3.1. Challenges Faced by ADC Manufacturers
8.2.4. Contract Manufacturing Scenario
8.2.4.1. Types of Contract Services Providers
8.2.4.1.1. ADC CMOs: Companies Providing Linker Production Services
8.2.4.1.2. ADC CMOs: Companies Providing HPAPI / Cytotoxic Drug Production Services
8.2.4.1.3. ADC CMOs: Companies Providing Conjugation Services
8.2.4.1.4. ADC CMOs: Full Services Providers
8.2.5. Key Drivers of the Contract Manufacturing Market for ADCs
8.2.5.1. Emergence of Startups
8.2.5.2. Investments and Facility Expansions
8.2.5.3. Partnerships and Collaborations
8.3. Bispecific Antibodies
8.3.1. Introduction
8.3.1.1. The Bispecific Advantage
8.3.1.2. Classification of Bispecific Antibodies
8.3.2. Pipeline Analysis
8.3.3. Bispecific Antibody Based Technology Providers
8.3.4. Contract Manufacturing Scenario
8.4. Cell Therapy
8.4.1. Introduction
8.4.2. Current Market Landscape
8.4.3. Cell Therapy Manufacturing
8.4.3.1. Cell Therapy Manufacturing: Key Challenges and Growth Drivers
8.4.4. Types of Manufacturers
8.4.2. Contract Manufacturing Scenario
8.5. Gene Therapy
8.5.1. Introduction
8.5.2. Pipeline Analysis
8.5.3. Contract Manufacturing Scenario
9. CASE STUDY: OUTSOURCING OF BIOSIMILARS
9.1. Chapter Overview
9.2. Biosimilars: An Introduction
9.3. Biosimilars: Need for Outsourcing of Development and Manufacturing Operations
9.4. Impact of Biosimilars on the Global Contract Manufacturing Market
9.4.1. Pipeline Analysis
9.4.2. Regional Trends
9.4.3. Contract Services Providers
9.5. Biosimilars: Challenges Associated with Outsourcing
10. RECENT DEVELOPMENTS
10.1. Chapter Overview
10.2. Biopharmaceutical Contract Manufacturing Market: Partnerships
10.2.1. Biopharmaceutical Contract Manufacturing Market: Growing Trend of Partnerships
10.2.2. Biopharmaceutical Contract Manufacturing Market: Analysis by Type of Partnership
10.3. Biopharmaceutical Contract Manufacturing Market: Recent Developments
10.3.1. Biopharmaceutical Contract Manufacturing Market: Growing Trend of Recent Developments
10.3.2. Biopharmaceutical Contract Manufacturing Market: Analysis by Type of Recent Development
10.4. Biopharmaceutical Contract Manufacturing Market: Funding Instances
10.5. Biopharmaceutical Contract Manufacturing Market: Technological Advances
10.5.1. Adoption of Single-use Technologies
10.5.2. Process Analytical Technologies
10.5.3. Continuous Processing
10.5.4. Quality by Design in Bio-processing
11. CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Methodology
11.3. Biopharmaceutical CMOs: Global Production Capacity
11.3.1. Analysis by Region
11.3.2. Analysis by Expression Systems
11.4. Conclusion
12. SURVEY ANALYSIS
12.1. Chapter Overview
12.1.1. Overview of Respondents
12.1.2. Designation of Respondents
12.2. Biologics Manufacturing Expertise
12.3. Scale of Manufacturing
12.4. Location of Production Facilities
12.5. Types of Expression Systems
12.6. Types of Bioreactors
12.7. Modes of Operation of Bioreactors
13. OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Forecast Methodology
13.3. Overall Biopharmaceutical Contract Manufacturing Market, 2017-2027
13.3.1. Biopharmaceutical Contract Manufacturing Market for API Manufacturing, 2017-2027
13.3.2. Biopharmaceutical Contract Manufacturing Market for FDF Manufacturing, 2017-2027
13.4. Biopharmaceutical Contract Manufacturing Market, 2017-2027: Analysis by Expression Systems
13.5. Biopharmaceutical Contract Manufacturing Market, 2017-2027: Regional Distribution
14. SWOT ANALYSIS
14.1. Chapter Overview
14.2. Strengths
14.3. Weaknesses
14.4. Opportunities
14.5. Threats
14.6. Conclusion
15. FUTURE OF THE BIOPHARMACEUTICAL CMO MARKET
15.1. Chapter Overview
15.2. Significant Growth in Outsourcing Activities
15.3. Evident Shift from One-time Contracts to Strategic Partnerships
15.4. New Technologies and Focus on Innovation to Support Further Growth in this Domain
15.5. Focus on Niche Therapeutic Areas to Sustain Growth
15.6. Growing Biosimilars Market to Contribute to the Growth of the Contract Services Segment
15.7. CMOs are Increasingly Expanding their Capabilities and Expertise in Order to become One Stop Shops
15.8. Offshoring of Outsourcing Activities to Maximize Profits and Expand Existing Capacities
15.9. Growing Demand for Biologics and Biosimilars to Influence Financial Inflow and Outsourcing Budgets
15.10. The Need for Humanized Products to Drive the Growth of Mammalian Expression Technologies
15.11. Despite the Positive Future Outlook, There are a Number of Challenges Faced by both Sponsors and Service Providers
15.12. Concluding Remarks
16. INTERVIEW TRANSCRIPTS
16.1. Chapter Overview
16.2. Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biotechnologie
16.3. Claire Otjes, Assistant Marketing Manager, Batavia Biosciences
16.4. David C Cunningham, Director Corporate Development, Goodwin Biotechnology
16.5. Dietmar Katinger, CEO, Polymun Scientific
16.6. Kevin Daley, Director Pharmaceuticals, Novasep Synthesis
16.7. Mark Wright, Site Lead, Grangemouth, Piramal Healthcare
16.8. Raquel Fortunato, CEO, GenIbet Biopharmaceuticals
16.9. Sebastian Schuck, Head of Business Development, Wacker Biotech
16.10. Stephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies
16.11. Tim Oldham, CEO, Cell Therapies
16.12. Anonymous
17. APPENDIX I TABULATED DATA
18. APPENDIX II LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 3.1 Types of Third Party Service Providers
Figure 3.2 Biopharmaceutical Contract Manufacturing: Commonly Outsourced Operations
Figure 4.1 Biopharmaceutical CMOs: Geographical Distribution of Facilities
Figure 4.2 Biopharmaceutical CMOs: Geographical Distribution of Facilities by Major Regions
Figure 4.3 Biopharmaceutical CMOs: Distribution by Types of Biologics
Figure 4.4 Biopharmaceutical CMOs: Distribution by Scale of Operation
Figure 4.5 Biopharmaceutical CMOs: Distribution by Expression Systems
Figure 4.6 Biopharmaceutical CMOs: Distribution by Types of Bioreactors
Figure 4.7 Biopharmaceutical CMOs: Distribution by Modes of Operation of Bioreactors
Figure 5.1 Biopharmaceutical Contract Manufacturing in the US: Growth Drivers and Challenges
Figure 5.2 AMRI: Services Portfolio
Figure 5.3 AMRI Annual Revenues, FY 2012-FY 2016 (USD Million)
Figure 5.4 AMRI: Revenues by Business Divisions, FY 2016 (USD Million)
Figure 5.5 Baxter International: Annual Revenues, FY 2012-FY 2016 (USD Million)
Figure 5.6 Catalent: Services Portfolio
Figure 5.7 Catalent: Annual Revenues, FY 2012-FY 2016 (USD Million)
Figure 5.8 Catalent: Revenues by Business Divisions, FY 2016 (USD million)
Figure 5.9 Cytovance: Services Portfolio
Figure 5.10 Patheon: Services Portfolio
Figure 5.11 Patheon Services and Solutions: Biologics
Figure 5.12 Patheon Services and Solutions: Small Molecules
Figure 5.13 Patheon: Annual Revenues, FY 2012-Q1 2017 (USD Million)
Figure 5.14 Patheon: Revenues by Business Divisions, FY 2016 (USD Million)
Figure 5.15 Biopharmaceutical Contract Manufacturing in the US: Distribution by Type of Business Operation, Base Scenario, 2017-2027 (USD Billion)
Figure 5.16 Biopharmaceutical Contract Manufacturing in the US: Distribution by Expression Systems, Base Scenario, 2017-2027 (USD Billion)
Figure 6.1 Biopharmaceutical Contract Manufacturing in Europe: Growth Drivers and Challenges
Figure 6.2 3P Biopharmaceuticals: Services Portfolio
Figure 6.3 Boehringer Ingelheim BioXcellence: Services Portfolio
Figure 6.4 Boehringer Ingelheim: Annual Revenues, FY 2012-FY 2016 (EUR Million)
Figure 6.5 Boehringer Ingelheim: Revenues by Business Divisions, FY 2016 (EUR Million)
Figure 6.6 Celonic: Services Portfolio
Figure 6.7 FUJIFILM Diosynth Biotechnologies: Services Portfolio
Figure 6.8 FUJIFILM Diosynth Biotechnologies: Annual Revenues, FY 2012- Q1-Q3 2017 (JPY Billion)
Figure 6.9 FUJIFILM Holdings: Revenues by Business Divisions, FY 2016 (JPY Billion)
Figure 6.10 LFB Group: Services Portfolio
Figure 6.11 CELLforCURE: Services Portfolio
Figure 6.12 LFB Biomanufacturing Services: Services Portfolio
Figure 6.13 LFB Group: Annual Revenues, FY 2012-FY 2016 (EUR Million)
Figure 6.14 LFB Group: Revenues by Therapeutic Area and Services, FY 2016 (EUR Million)
Figure 6.15 Lonza: Services Portfolio
Figure 6.16 Lonza: Annual Revenues, FY 2012-FY 2016 (CHF Million)
Figure 6.17 Lonza: Revenues by Business Divisions, FY 2016 (CHF Million)
Figure 6.18 Menarini Biotech: Services Portfolio
Figure 6.19 Novasep: Services Portfolio
Figure 6.20 Rentschler Biotechnologie: Services Portfolio
Figure 6.21 Biopharmaceutical Contract Manufacturing in Europe: Distribution by Country, Base Scenario, 2017-2027 (USD Billion)
Figure 6.22 Biopharmaceutical Contract Manufacturing in Europe: Distribution by Type of Business Operation, Base Scenario, 2017-2027 (USD Billion)
Figure 6.23 Biopharmaceutical Contract Manufacturing in Europe: Distribution by Expression Systems, Base Scenario, 2017-2027 (USD Billion)
Figure 7.1 Biopharmaceutical Contract Manufacturing in China: Growth Drivers and Challenges
Figure 7.2 Autotek Bio: Services Portfolio
Figure 7.3 Autotek Bio: DisposUp® Technology
Figure 7.4 WuXi Biologics: Services Portfolio
Figure 7.5 WuXi Biologics: Antibody Discovery Procedure
Figure 7.6 Biopharmaceutical Contract Manufacturing in China: Distribution by Type of Business Operation, Base Scenario, 2017-2027 (USD Billion)
Figure 7.7 Biopharmaceutical Contract Manufacturing in China: Distribution by Expression Systems, Base Scenario, 2017-2027 (USD Billion)
Figure 7.8 Biopharmaceutical Contract Manufacturing in India: Growth Drivers and Challenges
Figure 7.9 Intas Pharmaceuticals: Revenues from Operations, FY 2012-FY 2016 (INR Million)
Figure 7.10 Piramal Pharma Solutions: Annual Revenues, FY 2012-FY 2016 (INR Million)
Figure 7.11 Shasun Pharma: Revenues by Geography, FY 2015-FY 2016 (INR Billion)
Figure 7.12 Syngene: Services Portfolio
Figure 7.13 Syngene: Annual Revenues, FY 2012-Q1 2017 (INR Million)
Figure 7.14 Biopharmaceutical Contract Manufacturing in India: Distribution by Type of Business Operation, Base Scenario, 2017-2027 (USD Billion)
Figure 7.15 Biopharmaceutical Contract Manufacturing in India: Distribution by Expression Systems, Base Scenario, 2017-2027 (USD Billion)
Figure 7.16 Asahi Glass: Services Portfolio
Figure 7.17 Asahi Glass: Annual Revenues, FY 2012-Q1 2017 (JPY Million)
Figure 7.18 Biopharmaceutical Contract Manufacturing in Japan: Distribution by Type of Business Operation, Base Scenario, 2017-2027 (USD Billion)
Figure 7.19 Biopharmaceutical Contract Manufacturing in Japan: Distribution by Expression Systems, Base Scenario, 2017-2027 (USD Billion)
Figure 7.20 DMBio: Services Portfolio
Figure 7.21 DMBio: Manufacturing Services
Figure 7.22 Samsung BioLogics: Services Portfolio
Figure 7.23 Samsung BioLogics: Annual Revenues from CMO Operations, FY 2013-Q1 2017 (KRW Billion)
Figure 7.24 Biopharmaceutical Contract Manufacturing in South Korea: Distribution by Type of Business Operation, Base Scenario, 2017-2027 (USD Billion)
Figure 7.25 Biopharmaceutical Contract Manufacturing in South Korea: Distribution by Expression Systems, Base Scenario, 2017-2027 (USD Billion)
Figure 7.26 Cell Therapies: Cell Therapy Services
Figure 7.27 Luina Bio: Services Portfolio
Figure 8.1 Bispecific Antibodies Pipeline: Distribution by Phase of Development
Figure 8.2 Cell Therapy Manufacturing: Key Steps
Figure 8.3 Cell Therapy: Key Challenges and Growth Drivers
Figure 8.4 Cell Therapy Manufacturing: Types of Manufacturers
Figure 8.5 Gene Therapy Pipeline: Distribution by Phase of Development
Figure 8.6 Gene Therapy Contract Manufacturers: Distribution by Scale of Operation
Figure 8.7 Gene Therapy Contract Manufacturers: Distribution by Location
Figure 9.1 Global Biosimilars Pipeline: Distribution by Phase of Development
Figure 9.2 Global Biosimilars Pipeline: Distribution by Phase of Development and Product Category
Figure 9.3 Global Biosimilars Pipeline: Distribution by Phase of Development and Geography
Figure 10.1 Biopharmaceutical Contract Manufacturing Market: Cumulative Trend of Partnerships
Figure 10.2 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Partnership
Figure 10.3 Biopharmaceutical Contract Manufacturing Market: Cumulative Trend of Recent Developments
Figure 10.4 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Recent Development
Figure 10.5 Process Analytical Technologies: Key Advantages
Figure 10.6 Continuous Processing: Key Advantages
Figure 11.1 Capacity Analysis: Global Contract Biomanufacturing Capacity by Size of CMOs
Figure 11.2 Capacity Analysis: Regional Distribution of Biopharmaceutical CMOs (Small and Mid-sized CMOs)
Figure 11.3 Capacity Analysis: Regional Production Capacity of Biopharmaceutical CMOs (Small and Mid-sized CMOs)
Figure 11.4 Capacity Analysis: Regional Contract Biomanufacturing Capacity (Small and Mid-sized CMOs)
Figure 11.5 Capacity Analysis: Percentage Distribution by Expression Systems Used
Figure 12.1 Survey Analysis: Distribution of Respondents by Company Type
Figure 12.2 Survey Analysis: Distribution of Respondents by Location of Headquarters
Figure 12.3 Survey Analysis: Distribution of Respondents by Designation
Figure 12.4 Survey Analysis: Distribution by Biologics Manufacturing Expertise
Figure 12.5 Survey Analysis: Distribution by Scale of Manufacturing
Figure 12.6 Survey Analysis: Distribution by Location of Production Facilities
Figure 12.7 Survey Analysis: Distribution by Types of Expression Systems
Figure 12.8 Survey Analysis: Distribution by Types of Bioreactors
Figure 12.9 Survey Analysis: Distribution by Modes of Operation of Bioreactors
Figure 13.1 Biopharmaceutical Contract Manufacturing Market: Share of Contract Manufacturers
Figure 13.2 Global Biopharmaceutical Contract Manufacturing Market, 2017-2027: Base Scenario (USD Billion)
Figure 13.3 Global Biopharmaceutical Contract Manufacturing Market for API, 2017-2027: Base Scenario (USD Billion)
Figure 13.4 Global Biopharmaceutical Contract Manufacturing Market for FDF, 2017-2027: Base Scenario (USD Billion)
Figure 13.5 Distribution of Global Biopharmaceutical Contract Manufacturing Market by Expression Systems, 2017-2027: Base Scenario (USD Billion)
Figure 13.6 Regional Distribution of Biopharmaceutical Contract Manufacturing Market, 2017-2027: Base Scenario (USD Billion)
Figure 14.1 Global Biopharmaceuticals Market: Number of FDA Approvals by Year, 2002-2016
LIST OF TABLES
Table 4.1 Biopharmaceutical CMOs: Geographical Presence
Table 4.2 Biopharmaceutical CMOs: Types of Biologics
Table 4.3 Biopharmaceutical CMOs: Scale of Operation
Table 4.4 Biopharmaceutical CMOs: Types of Expression Systems
Table 4.5 Biopharmaceutical CMOs: Types of Bioreactors
Table 4.6 Biopharmaceutical CMOs: Modes of Operation
Table 4.7 Biopharmaceutical CMOs: Contract Biomanufacturing Capacity
Table 4.8 Biopharmaceutical CMOs: Types of Packaging Forms
Table 5.1 Catalent: Biopharmaceutical Facilities
Table 5.2 Patheon: Biopharmaceutical Facilities
Table 6.1 FDA Quality Agreement versus EMA cGMP Regulations: A Comparative Analysis
Table 6.2 Boehringer Ingelheim BioXcellence: Biopharmaceutical Facilities
Table 6.3 Celonic: Biopharmaceutical Facilities
Table 6.4 FUJIFILM Diosynth Biotechnologies: Biomanufacturing Capabilities
Table 6.5 Lonza: Biopharmaceutical Facilities
Table 7.1 Intas Pharmaceuticals: Biopharmaceutical Facilities
Table 7.2 Kemwell Biopharma: Biopharmaceutical Facilities
Table 7.3 Piramal Pharma Solutions: Biopharmaceutical Facilities
Table 7.4 Shasun Pharma: Biopharmaceutical Facilities
Table 7.5 Samsung BioLogics: Biopharmaceutical Facilities
Table 8.1 ADC Pipeline: Marketed and Clinical Molecules
Table 8.2 ADC Pipeline: Preclinical and Discovery Stage Molecules
Table 8.3 ADC Contract Manufacturers: Overview of Capabilities
Table 8.4 ADC Contract Manufacturers: Conjugation Services Providers
Table 8.5 ADC Contract Manufacturers: Full Services CMOs
Table 8.6 Bispecific Antibodies Pipeline
Table 8.7 Bispecific Antibody Technologies and Technology Providers
Table 8.8 Cell Therapies: Applications
Table 8.9 Cell Therapies: Commercialized Products
Table 8.10 Cell Therapy Manufacturing: Assessment Strategies for Different Manufacturing Processes
Table 8.11 Cell Therapy Contract Manufacturers
Table 8.12 Gene Therapy Contract Manufacturers
Table 9.1 Contract Services Providers for Biosimilars
Table 10.1 Biopharmaceutical Contract Manufacturing Market: Partnerships
Table 10.2 Biopharmaceutical Contract Manufacturing Market: Recent Developments
Table 10.2 Biopharmaceutical Contract Manufacturing Market: Funding Instances
Table 11.1 Capacity Analysis: CMO Size Adjustments based on Capacity
Table 11.2 Capacity Analysis: CMO Size Adjustments based on Employee Base
Table 11.3 Capacity Analysis: Average Capacity per Category
Table 11.4 Capacity Analysis: Global Contract Biomanufacturing Capacity
Table 11.4 Capacity Analysis: Regional Contract Biomanufacturing Capacity (Small and Mid-sized CMOs)
Table 12.1 Survey Analysis: Overview of Respondents
Table 12.2 Survey Analysis: Distribution of Respondents by Designation
Table 12.3 Survey Analysis: Biologics Manufacturing Expertise
Table 12.4 Survey Analysis: Scale of Manufacturing
Table 12.5 Survey Analysis: Location of Production Facilities
Table 12.6 Survey Analysis: Types of Expression Systems
Table 12.7 Survey Analysis: Types of Bioreactors
Table 12.8 Survey Analysis: Modes of Operation of Bioreactors
Table 14.1 Biopharmaceutical Contract Manufacturing Market: SWOT Analysis
Table 14.2 Global Biopharmaceuticals Market: Patent Approval and Expiry Details of Best- selling Biologics
Table 17.1 Biopharmaceutical CMOs: Geographical Distribution of Facilities
Table 17.2 Biopharmaceutical CMOs: Geographical Distribution of Facilities by Major Regions
Table 17.3 Biopharmaceutical CMOs: Distribution by Types of Biologics
Table 17.4 Biopharmaceutical CMOs: Distribution by Scale of Operation
Table 17.5 Biopharmaceutical CMOs: Distribution by Expression Systems
Table 17.6 Biopharmaceutical CMOs: Distribution by Types of Bioreactors
Table 17.7 Biopharmaceutical CMOs: Distribution by Modes of Operation
Table 17.8 AMRI Annual Revenues, FY 2012-Q1 2017 (USD Million)
Table 17.9 AMRI: Revenues by Business Segments, FY 2016 (USD Million)
Table 17.10 Baxter International: Revenues, FY 2012 – Q1 2017 (USD Million)
Table 17.11 Catalent: Revenues, FY 2012 – Q1-Q3 2017 (USD Million)
Table 17.12 Catalent: Revenues by Business Divisions, FY 2016 (USD Million)
Table 17.13 Patheon: Annual Revenues, FY 2012 – Q1 2017 (USD Million)
Table 17.14 Patheon: Revenues by Business Segments, FY 2016 (USD Million)
Table 17.15 Biopharmaceutical Contract Manufacturing in North America: Distribution by Type of Business Operation, Conservative Scenario, 2017-2027 (USD Billion)
Table 17.16 Biopharmaceutical Contract Manufacturing in North America: Distribution by Type of Business Operation, Base Scenario, 2017-2027 (USD Billion)
Table 17.17 Biopharmaceutical Contract Manufacturing in North America: Distribution by Type of Business Operation, Optimistic Scenario, 2017-2027 (USD Billion)
Table 17.18 Biopharmaceutical Contract Manufacturing in the US: Distribution by Expression Systems, Conservative Scenario, 2017-2027 (USD Billion)
Table 17.19 Biopharmaceutical Contract Manufacturing in the US: Distribution by Expression Systems, Base Scenario, 2017-2027 (USD Billion)
Table 17.20 Biopharmaceutical Contract Manufacturing in the US: Distribution by Expression Systems, Optimistic Scenario, 2017-2027 (USD Billion)
Table 17.21 Boehringer Ingelheim: Annual Revenues, FY 2012 – FY 2016 (EUR Million)
Table 17.22 Boehringer Ingelheim: Revenues by Business Divisions, FY 2016 (EUR Million)
Table 17.23 FUJIFILM Group: Revenues, FY 2012 – Q1-Q3 2017 (JPY Billion)
Table 17.24 FUJIFILM Holdings: Revenue by Business Divisions, FY 2016 (JPY Billion)
Table 17.25 LFB Group: Annual Revenues, FY 2012 – FY 2015 (EUR Million)
Table 17.26 LFB Group: Revenues by Therapeutic Area and Services, FY 2015 (EUR Million)
Table 17.27 Lonza: Annual Revenues, FY 2012 – FY2016 (CHF Million)
Table 17.28 Lonza: Revenues by Business Divisions, 2016 (CHF Million)
Table 17.29 Biopharmaceutical Contract Manufacturing in Europe: Distribution by Country, Conservative Scenario, 2017-2027 (USD Billion)
Table 17.30 Biopharmaceutical Contract Manufacturing in Europe: Distribution by Country, Base Scenario, 2017-2027 (USD Billion)
Table 17.31 Biopharmaceutical Contract Manufacturing in Europe: Distribution by Country, Optimistic Scenario, 2017-2027 (USD Billion)
Table 17.32 Biopharmaceutical Contract Manufacturing in Europe: Distribution by Type of Business Operation, Conservative Scenario, 2017-2027 (USD Billion)
Table 17.33 Biopharmaceutical Contract Manufacturing in Europe: Distribution by Type of Business Operation, Base Scenario, 2017-2027 (USD Billion)
Table 17.34 Biopharmaceutical Contract Manufacturing in Europe: Distribution by Type of Business Operation, Optimistic Scenario, 2017-2027 (USD Billion)
Table 17.35 Biopharmaceutical Contract Manufacturing in Europe: Distribution by Expression Systems, Conservative Scenario, 2017-2027 (USD Billion)
Table 17.36 Biopharmaceutical Contract Manufacturing in Europe: Distribution by Expression Systems, Base Scenario, 2017-2027 (USD Billion)
Table 17.37 Biopharmaceutical Contract Manufacturing in Europe: Distribution by Expression Systems, Optimistic Scenario, 2017-2027 (USD Billion)
Table 17.38 Biopharmaceutical Contract Manufacturing in China: Distribution by Type of Business Operation, Conservative Scenario, 2017-2027 (USD Billion)
Table 17.39 Biopharmaceutical Contract Manufacturing in China: Distribution by Type of Business Operation, Base Scenario, 2017-2027 (USD Billion)
Table 17.40 Biopharmaceutical Contract Manufacturing in China: Distribution by Type of Business Operation, Optimistic Scenario, 2017-2027 (USD Billion)
Table 17.41 Biopharmaceutical Contract Manufacturing in China: Distribution by Expression Systems, Conservative Scenario, 2017-2027 (USD Billion)
Table 17.42 Biopharmaceutical Contract Manufacturing in China: Distribution by Expression Systems, Base Scenario, 2017-2027 (USD Billion)
Table 17.43 Biopharmaceutical Contract Manufacturing in China: Distribution by Expression Systems, Optimistic Scenario, 2017-2027 (USD Billion)
Table 17.44 Intas Pharmaceuticals: Revenue from Operations, FY 2012 – FY 2016 (INR Million)
Table 17.45 Piramal Pharma Solutions: Annual Revenues, FY 2012- FY 2016 (INR Million)
Table 17.46 Shasun Pharma: Revenues by Geography, FY 2015-FY 2016 (INR Billion)
Table 17.47 Syngene: Annual Revenues FY 2012-Q1 2017 (INR Million)
Table 17.48 Biopharmaceutical Contract Manufacturing in India: Distribution by Type of Business Operation, Conservative Scenario, 2017-2027 (USD Billion)
Table 17.49 Biopharmaceutical Contract Manufacturing in India: Distribution by Type of Business Operation, Base Scenario, 2017-2027 (USD Billion)
Table 17.50 Biopharmaceutical Contract Manufacturing in India: Distribution by Type of Business Operation, Optimistic Scenario, 2017-2027 (USD Billion)
Table 17.51 Biopharmaceutical Contract Manufacturing in India: Distribution by Expression Systems, Conservative Scenario, 2017-2027 (USD Billion)
Table 17.52 Biopharmaceutical Contract Manufacturing in India: Distribution by Expression Systems, Base Scenario, 2017-2027 (USD Billion)
Table 17.53 Biopharmaceutical Contract Manufacturing in India: Distribution by Expression Systems, Optimistic Scenario, 2017-2027 (USD Billion)
Table 17.54 Asahi Glass Company: Annual Revenues, FY 2012-Q1 2017 (JPY Million)
Table 17.55 Biopharmaceutical Contract Manufacturing in Japan: Distribution by Type of Business Operation, Conservative Scenario, 2017-2027 (USD Billion)
Table 17.56 Biopharmaceutical Contract Manufacturing in Japan: Distribution by Type of Business Operation, Base Scenario, 2017-2027 (USD Billion)
Table 17.57 Biopharmaceutical Contract Manufacturing in Japan: Distribution by Type of Business Operation, Optimistic Scenario, 2017-2027 (USD Billion)
Table 17.58 Biopharmaceutical Contract Manufacturing in Japan: Distribution by Expression Systems, Conservative Scenario, 2017-2027 (USD Billion)
Table 17.59 Biopharmaceutical Contract Manufacturing in Japan: Distribution by Expression Systems, Base Scenario, 2017-2027 (USD Billion)
Table 17.60 Biopharmaceutical Contract Manufacturing in Japan: Distribution by Expression Systems, Optimistic Scenario, 2017-2027 (USD Billion)
Table 17.61 Samsung BioLogics: Revenues from CMO, FY 2013-Q1 2017 (KRW Billion)
Table 17.62 Biopharmaceutical Contract Manufacturing in South Korea: Distribution by Type of Business Operation, Conservative Scenario, 2017-2027 (USD Billion)
Table 17.63 Biopharmaceutical Contract Manufacturing in South Korea: Distribution by Type of Business Operation, Base Scenario, 2017-2027 (USD Billion)
Table 17.64 Biopharmaceutical Contract Manufacturing in South Korea: Distribution by Type of Business Operation, Optimistic Scenario, 2017-2027 (USD Billion)
Table 17.65 Biopharmaceutical Contract Manufacturing in South Korea: Distribution by Expression Systems, Conservative Scenario, 2017-2027 (USD Billion)
Table 17.66 Biopharmaceutical Contract Manufacturing in South Korea: Distribution by Expression Systems, Base Scenario, 2017-2027 (USD Billion)
Table 17.67 Biopharmaceutical Contract Manufacturing in South Korea: Distribution by Expression Systems, Optimistic Scenario, 2017-2027 (USD Billion)
Table 17.68 Bispecific Antibodies Pipeline: Distribution by Phase of Development
Table 17.69 Gene Therapy Pipeline: Distribution by Phase of Development
Table 17.70 Gene Therapy Contract Manufacturers: Distribution by Scale of Operation
Table 17.71 Gene Therapy Contract Manufacturers: Distribution by Location
Table 17.72 Global Biosimilars Pipeline: Distribution by Phase of Development
Table 17.73 Global Biosimilars Pipeline: Distribution by Phase of Development and Product Category
Table 17.74 Global Biosimilars Pipeline: Distribution by Phase of Development and Geography
Table 17.75 Biopharmaceutical CMOs: Cumulative Investment by Year
Table 17.76 Biopharmaceutical CMOs Investments: Distribution by Type
Table 17.77 Biopharmaceutical CMOs Partnerships: Distribution by Type of Partnerships
Table 17.78 Biopharmaceutical CMOs Partnerships: Cumulative Distribution by Year
Table 17.79 Capacity Analysis: Global Contract Biomanufacturing Capacity by Size of CMOs
Table 17.80 Capacity Analysis: Regional Distribution of Biopharmaceutical CMOs
Table 17.81 Capacity Analysis: Regional Production Capacity of Biopharmaceutical CMOs
Table 17.82 Capacity Analysis: Regional Contract Biomanufacturing Capacity
Table 17.83 Capacity Analysis: Percentage Distribution by Expression Systems Used
Table 17.84 Survey Analysis: Distribution of Respondents by Company Type
Table 17.85 Survey Analysis: Distribution of Respondents by Location of Headquarters
Table 17.86 Survey Analysis: Distribution of Respondents by Designation
Table 17.87 Survey Analysis: Distribution by Biologics Manufacturing Expertise
Table 17.88 Survey Analysis: Distribution by Scale of Manufacturing
Table 17.89 Survey Analysis: Distribution by Location of Production Facilities
Table 17.90 Survey Analysis: Distribution by Types of Expression Systems
Table 17.91 Survey Analysis: Distribution by Types of Bioreactors
Table 17.92 Survey Analysis: Distribution by Modes of Operation of Bioreactors
Table17.93 Global Biopharmaceutical Contract Manufacturing Market, 2017-2027: Conservative Scenario (USD Billion)
Table 17.94 Global Biopharmaceutical Contract Manufacturing Market, 2017-2027: Base Scenario (USD Billion)
Table 17.95 Global Biopharmaceutical Contract Manufacturing Market, 2017-2027: Optimistic Scenario (USD Billion)
Table 17.96 Global Biopharmaceutical Contract Manufacturing Market for API, 2017-2027: Conservative Scenario (USD Billion)
Table 17.97 Global Biopharmaceutical Contract Manufacturing Market for API, 2017-2027: Base Scenario (USD Billion)
Table 17.98 Global Biopharmaceutical Contract Manufacturing Market for API, 2017-2027: Optimistic Scenario (USD Billion)
Table 17.99 Global Biopharmaceutical Contract Manufacturing Market for FDF, 2017-2027: Conservative Scenario (USD Billion)
Table 17.100 Global Biopharmaceutical Contract Manufacturing Market for FDF, 2017-2027: Base Scenario (USD Billion)
Table 17.101 Global Biopharmaceutical Contract Manufacturing Market for FDF, 2017-2027: Optimistic Scenario (USD Billion)
Table 17.102 Distribution of Global Biopharmaceutical Contract Manufacturing Market by Expression Systems, 2017-2027: Conservative Scenario (USD Billion)
Table 17.103 Distribution of Global Biopharmaceutical Contract Manufacturing Market by Expression Systems, 2017-2027: Base Scenario (USD Billion)
Table 17.104 Distribution of Global Biopharmaceutical Contract Manufacturing Market by Expression Systems, 2017-2027: Optimistic Scenario (USD Billion)
Table 17.105 Regional Distribution of Biopharmaceutical Contract Manufacturing Market, 2017-2027: Conservative Scenario (USD Billion)
Table 17.106 Regional Distribution of Biopharmaceutical Contract Manufacturing Market, 2017-2027: Base Scenario (USD Billion)
Table 17.107 Regional Distribution of Biopharmaceutical Contract Manufacturing Market, 2017-2027: Optimistic Scenario (USD Billion)
Table 17.108 Regional Distribution of Biopharmaceutical Contract Manufacturing Market, 2017, 2022 and 2027: Conservative Scenario (USD Billion)
Table 17.109 Regional Distribution of Biopharmaceutical Contract Manufacturing Market, 2017, 2022 and 2027: Base Scenario (USD Billion)
Table 17.110 Regional Distribution of Biopharmaceutical Contract Manufacturing Market, 2017, 2022 and 2027: Optimistic Scenario (USD Billion)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report